Cardiff Oncology Reports Short Cash Runway, Advances Lead Drug to Phase 3 with FDA Alignment

summarizeSummary

Cardiff Oncology reported Q1 2026 results, revealing a short cash runway into Q1 2027, but also announced significant clinical progress with FDA alignment for a Phase 3 trial of its lead drug, onvansertib, and upcoming detailed Phase 2 data at ASCO.

check_boxKey Events

• Q1 2026 Financial Results

  The company reported approximately $46.1 million in cash, cash equivalents, and short-term investments as of March 31, 2026.

• Short Cash Runway

  Current cash resources are projected to fund operations only into the first quarter of 2027, indicating a critical need for additional financing.

• FDA Alignment for Phase 3 Trial

  Cardiff Oncology completed a successful End-of-Phase 2 meeting with the FDA, aligning on the 30 mg dose of onvansertib with FOLFIRI/bev chemotherapy for the planned Phase 3 trial in first-line RAS-mutated metastatic colorectal cancer.

• Upcoming ASCO Presentation

  The company will present detailed updated data from its randomized Phase 2 CRDF-004 trial at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29–June 2.

auto_awesomeAnalysis

Cardiff Oncology reported Q1 2026 financial results, revealing approximately $46.1 million in cash and a cash runway projected only into the first quarter of 2027. This short runway, coupled with the 'going concern' warning in the concurrent 10-Q, highlights significant financial challenges and an urgent need for additional financing. Despite this, the company announced positive clinical progress, including a successful End-of-Phase 2 meeting with the FDA, aligning on the design and dose for a pivotal Phase 3 trial for its lead asset, onvansertib. Further detailed Phase 2 data will be presented at the upcoming ASCO Annual Meeting. The market will weigh the positive clinical momentum against the critical need for capital to fund the planned Phase 3 trial.